During this week’s annual meeting of American Society of Hematology, researchers from Canada reported that using biosimilar filgrastim could result in substantial savings.
The role of biosimilars in Canadian healthcare systems has been increasingly in the spotlight in recent months, with an advisory council recommending biosimilar use as a way to achieve universal public coverage for pharmaceuticals, but with some patient groups—and reference product sponsors—opposing provincial switching programs that seek to transition patients to biosimilar products.
It is in this milieu that, during this week’s annual meeting of American Society of Hematology, researchers from Canada reported that using biosimilar filgrastim could result in substantial savings. The study, conducted by researchers from the University of Saskatchewan and the University of Alberta, focused on the Health Canada—approved biosimilar Grastofil, made by Apotex, which was introduced in Canada in 2016.
In a retrospective analysis of IQVIA data on Canadian drug purchases from 2016 to 2018, the investigators stratified samples by region, market size, and center type, and calculated cost savings on a quarterly basis by province.
They found that, during the period studied, the biosimilar accounted for 27% of filgrastim purchases, and a total of $62,061,576 (USD $47,127,078) in spending, while the brand-name filgrastim, Neupogen, accounted for $204,152,590 (USD $155,025,310). Biosimilar use therefore generated $13,443,873 (USD $10,208,739) in savings, but could have generated $36,348,476 (USD $27,601,578) had the biosimilar been used in 100% of cases.
The researchers note that the overall percentage of biosimilar filgrastim used in each Canadian province varied widely; market share for the biosimilar was as low as 0.08% in Nova Scotia and as high as 81.62% in Saskatchewan. In the largest Canadian province, Ontario, the biosimilar represented 44.7% of filgrastim use during the study period.
According to the authors, using biosimilars is an opportunity to save money in an overextended healthcare system, and while using Grastofil did generate some savings, increased biosimilar use will produce greater financial benefits.
Reference
Bhimji H, Eurich D, Mansell K, Mansell H. Potential and realized cost savings with the use of the biosimilar Grastofil vs Neupogen. Presented at: The 61th Annual Meeting and Exposition of the American Society of Hematology; December 7-10, 2019; Orlando, FL. Abstract 2126.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.